SRZN Surrozen, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SRZN matters now
Surrozen, Inc. (SRZN) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.19 with -1.32% on the session and $173.4M in market capitalization; recent performance reads 1-month -9.07% and YTD +2.88%.
The latest financial table shown here is Q1 2026, with revenue of $5.0M, net income of $-127.5M, and EPS of $-11.65. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.4%.
The latest indexable market news headline is "Surrozen to Present at Upcoming Healthcare Investor Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $42.00; recent insider activity includes Parker Craig C filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.92
P/S
23.20
EV/EBITDA
-0.22
DCF Value
$11.40
FCF Yield
-19.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.1%
Operating Margin
-573.8%
Net Margin
-4571.1%
ROE
309.8%
ROA
-283.8%
ROIC
-38.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $5.0M | $-127.5M | $-11.65 |
| Q4 2025 | $528.0K | $-183.2M | $-23.87 |
| FY 2025 | $3.5M | $-242.0M | $-32.37 |
| Q3 2025 | $983.0K | $-71.6M | $-8.36 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$42.00
Target (Median)
$42.00
Target Range
$40.00 - $44.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.51
Surrozen, Inc. is a biotechnology firm dedicated to discovering and advancing pharmaceutical agents that precisely modify the Wnt pathway to facilitate tissue healing and regeneration. The company engineers specialized antibodies intended for use across a broad spectrum of medical conditions impacting organs such as the intestine, liver, eyes (retina, cornea), lungs, kidneys, inner ear (cochlea), skin, pancreas, and central nervous system. Key assets in their development pipeline include SZN-043, a tissue-targeted R-spondin mimetic designed to address severe liver ailments. Another significant candidate is SZN-1326, a distinctive full-length human bi-specific antibody engineered to directly influence Wnt signaling in specific intestinal tissues by engaging with particular Frizzled and LRP receptors found in intestinal crypts. Surrozen, Inc. was established in 2015 and conducts its operations from its base in South San Francisco, California.